Yoshiyuki Tsujihata

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. doi request reprint TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats
    Yoshiyuki Tsujihata
    Metabolic Disease Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan
    J Pharmacol Exp Ther 339:228-37. 2011
  2. doi request reprint Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:3960-74. 2012
  3. doi request reprint Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:1538-52. 2012
  4. pmc A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1
    Chiori Yabuki
    Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
    PLoS ONE 8:e76280. 2013
  5. doi request reprint The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets
    Hiroaki Yashiro
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Pharmacol Exp Ther 340:483-9. 2012
  6. doi request reprint Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists
    Shinobu Sasaki
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 54:1365-78. 2011
  7. doi request reprint Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas
    Ryo Ito
    Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
    J Pharmacol Exp Ther 357:217-27. 2016

Collaborators

Detail Information

Publications7

  1. doi request reprint TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats
    Yoshiyuki Tsujihata
    Metabolic Disease Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan
    J Pharmacol Exp Ther 339:228-37. 2011
    ..TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity...
  2. doi request reprint Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:3960-74. 2012
    ..Compound 16 (TAK-875) is being evaluated in human clinical trials for the treatment of type 2 diabetes...
  3. doi request reprint Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:1538-52. 2012
    ....
  4. pmc A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1
    Chiori Yabuki
    Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
    PLoS ONE 8:e76280. 2013
    ..These findings contribute to our understanding of fasiglifam as an attractive antidiabetic drug with a novel mechanism of action. ..
  5. doi request reprint The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets
    Hiroaki Yashiro
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Pharmacol Exp Ther 340:483-9. 2012
    ....
  6. doi request reprint Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists
    Shinobu Sasaki
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 54:1365-78. 2011
    ..These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia...
  7. doi request reprint Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas
    Ryo Ito
    Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan
    J Pharmacol Exp Ther 357:217-27. 2016
    ..These results indicate that GPR40 agonists could be more effective and durable than SUs. Our results also provide new insights into GPR40 pharmacology and rationale for the use of GPR40 agonists in diabetic patients with SU failure. ..